<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748371</url>
  </required_header>
  <id_info>
    <org_study_id>GM15431-JAO1</org_study_id>
    <nct_id>NCT00748371</nct_id>
  </id_info>
  <brief_title>Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration</brief_title>
  <official_title>Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin has shown to be beneficial to some patients with certain diseases such as coronary
      artery disease or stroke. We are investigating how aspirin works on regulating platelets and
      thromboxane over time at different doses. We hope to find the best dose of aspirin and/or
      other medications to help people who are at risk for heart attack or stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      he purpose of the study is to better understand the mechanism for failure of daily aspirin
      administration to prevent cardiovascular events in some at risk individuals. We seek to
      describe the effect of chronic aspirin administration at varying doses on platelet
      aggregation. This will help to define mechanisms for aspirin failure and to pursue possible
      alternative therapies in patients who fail to respond to aspirin therapy.

      We hypothesize that (1) inhibition by aspirin (ASA) of ex vivo-induced platelet aggregation
      varies in a predictable time and dose dependent manner, (2) thromboxane and prostacyclin
      production is inhibited by ASA in a dose-dependent manner and remains relatively constant
      over time once maximal inhibition has occurred, and (3) granule secretion by platelets during
      induced aggregation is inhibited by aspirin acutely but this effect does not persist during
      chronic administration at high doses.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding issue
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of platelet aggregation, serum thromboxane B2 (TxB2) levels, urinary thromboxane metabolite (Tx-M) levels, and urinary prostacyclin metabolite (PGI-M) levels over time and across dose ranges.</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 40mg daily for 8 weeks followed by 3 weeks of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 1300mg daily for 8 weeks followed by 3 weeks of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: one Avicel (cellulose) capsule by mouth twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening</description>
    <arm_group_label>1</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>1300mg aspirin: one 650-mg capsule by mouth twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo: one Avicel (cellulose) capsule by mouth twice daily</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Avicel</other_name>
    <other_name>cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males

          -  Age 18-40 years

          -  Non-smokers

        Exclusion Criteria:

          -  ASA/NSAID use previous 14 days.

          -  Evidence of ASA/NSAID use within previous 14 days at baseline visit based on
             investigator interpretation of platelet aggregation and platelet secretion studies.

          -  History of chronic NSAID use.

          -  Currently taking NSAIDs, corticosteroids, or anticoagulants.

          -  History of coronary artery disease, myocardial infarction, coronary artery bypass
             grafting, percutaneous angioplasty, diabetes mellitus or stroke.

          -  History of gastric,duodenal, or esophageal ulcers or serious gastrointestinal bleed.

          -  History of frequent headaches, pain syndrome, or other condition requiring frequent
             use of analgesics.

          -  History of adverse reaction to ASA.

          -  Initial platelet count &lt;100K/µl or &gt;500K/µl.

          -  Initial hematocrit &lt;35% or &gt;50%.

          -  Weight less than 110 pounds.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Oates, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>John Oates</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>platelet aggregation</keyword>
  <keyword>granule secretion</keyword>
  <keyword>thromboxane production</keyword>
  <keyword>prostacyclin production</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

